cardiovascular effectとは 意味・読み方・使い方

MONOBASE POLYMORPHISM FOR PREDICTING CARDIOVASCULAR DISEASE AND THERAPEUTIC EFFECT例文帳に追加

心血管疾患を予測する一塩基多型および治療効果 - 特許庁

To provide a composition useful for preventing the development and/or recurrence of a cardiovascular event, especially for the cardiovascular event developed or recurred irrespective of the treatment of a hyperlipemia patient by HMG-CoA RI, or for a cardiovascular event which especially occurs after an unstable period after a cardiovascular reconstruction, and/or for a cardiovascular event development for which preventive effect of recurrence is expected, and/or for prevention of recurrence.例文帳に追加

心血管イベント発症および／または再発の予防に有用で、特に、高脂血症患者でＨＭＧ−ＣｏＡ ＲＩによる治療を行なったにもかかわらず発症および／または再発する心血管イベント、あるいは特に心血管再建術施行後不安定期を経過した後に起こる心血管イベントの発症および／または再発の予防効果が期待される心血管イベント発症および／または再発予防用組成物の提供。 - 特許庁

To provide a composition for health food derived from a natural product, enabling prevention and prophylaxis of obesity without fear of side effect or excessive dietary restriction and useful for prophylaxis and amelioration of chronic diseases such as high blood pressure, hyperlipemia, diabetes and cardiovascular disease and heart disease which are called lifestyle-related diseases.例文帳に追加

副作用の恐れがなく、過度な食事制限をすることなく肥満を防止、予防し、かつ、生活習慣病と言われる高血圧、高脂血症、糖尿病、循環器疾患、心臓疾患などの慢性疾患の予防や改善に有用な天然物由来の健康食品用組成物の提供。 - 特許庁

To provide new medications that can safely, conveniently and effectively treat and prevent disorders related to elevation of blood uric acid such as disorders due to urate crystals such as gouty arthritis, and diseases related to pathological effect of soluble uric acid such as cardiovascular and renal diseases.例文帳に追加

痛風性関節炎等の尿酸結晶が原因の障害、及び、心血管疾患及び腎疾患など可溶性尿酸の病理学的効果に関連する疾患等の血中尿酸の上昇に関連する障害を安全、手軽及び効果的に治療及び予防することができる新しい薬物の提供。 - 特許庁

To provide a calcium ion-independent smooth muscle anomalous shrinkage inhibitor that is uneffective on the calcium ion-independent physiological smooth muscle shrinkage, an injection composition for treating the cardiovascular diseases caused by smooth muscle anomalous shrinkage, a prophylactic and/or therapeutic agent for black out and narrowed visual field, reduction of the side-effect of the chemical-inducing orthostatic hypotension and Rho- kinase signal transduction system inhibitor.例文帳に追加

カルシウムイオン依存性の生理的な平滑筋収縮に影響しない、カルシウムイオン非依存性の平滑筋異常収縮の抑制剤、血管平滑筋異常収縮に起因する循環器系疾患治療用の注射用組成物、暗黒視症および視野狭窄の予防および／または治療剤、薬物誘発起立性低血圧の副作用軽減剤およびＲｈｏキナーゼシグナル伝達系の阻害剤の提供。 - 特許庁